192 related articles for article (PubMed ID: 32637578)
1. DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4.
Panneerselvam J; Mohandoss P; Patel R; Gillan H; Li M; Kumar K; Nguyen D; Weygant N; Qu D; Pitts K; Lightfoot S; Rao C; Houchen C; Bronze M; Chandrakesan P
Mol Ther Oncolytics; 2020 Sep; 18():24-36. PubMed ID: 32637578
[TBL] [Abstract][Full Text] [Related]
2. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
3. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of Long Non-Coding RNA
Zhan Y; Abuduwaili K; Wang X; Shen Y; Nuerlan S; Liu C
Cancer Manag Res; 2020; 12():7725-7737. PubMed ID: 32943921
[TBL] [Abstract][Full Text] [Related]
5. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
Ma Z; Cai H; Zhang Y; Chang L; Cui Y
Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
[TBL] [Abstract][Full Text] [Related]
6. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
8. Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
Wang L; Zhao L; Lin Z; Yu D; Jin M; Zhou P; Ren J; Cheng J; Yang K; Wu G; Zhang T; Zhang D
Clin Transl Med; 2022 May; 12(5):e743. PubMed ID: 35522902
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.
Yan R; Fan X; Xiao Z; Liu H; Huang X; Liu J; Zhang S; Yao J; An G; Ge Y
Cancer Lett; 2022 Apr; 531():83-97. PubMed ID: 35157971
[TBL] [Abstract][Full Text] [Related]
10. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC).
Zhao Y; Zheng R; Chen J; Ning D
Cancer Cell Int; 2020; 20():289. PubMed ID: 32655321
[TBL] [Abstract][Full Text] [Related]
11. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity.
Ding L; Yang Y; Ge Y; Lu Q; Yan Z; Chen X; Du J; Hafizi S; Xu X; Yao J; Liu J; Cao Z; Weygant N
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830884
[TBL] [Abstract][Full Text] [Related]
13. XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.
Yang WQ; Zhao WJ; Zhu LL; Xu SJ; Zhang XL; Liang Y; Ding XF; Kiselyov A; Chen G
Front Pharmacol; 2021; 12():603453. PubMed ID: 33762936
[TBL] [Abstract][Full Text] [Related]
14. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
Abdul Satar N; Ismail MN; Yahaya BH
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
[TBL] [Abstract][Full Text] [Related]
16. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
[TBL] [Abstract][Full Text] [Related]
17. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
18. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
19. MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer.
Wang H; Chen J; Zhang S; Zheng X; Xie S; Mao J; Cai Y; Lu X; Hu L; Shen J; Chai K; Chen W
Cancer Cell Int; 2020; 20():258. PubMed ID: 32577098
[TBL] [Abstract][Full Text] [Related]
20. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.
MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Cancer Lett; 2018 Aug; 428():117-126. PubMed ID: 29653268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
